Is AbbVie Stock a Buy Now?

AbbVie (NYSE: ABBV) closed out a pivotal 2024 with an excellent fourth-quarter earnings report. For the period ended Dec. 31, the biopharmaceuticals giant delivered 6% sales growth and $2.12 in adjusted earnings per share (EPS), with both metrics exceeding initial guidance. Comments by management projected optimism for continued growth momentum into the new year.With the shares kicking off 2025 with a solid 8% gain year to date, some investors may wonder -- can the rally keep going, and is AbbVie stock a buy right now? Here's what you need to know.AbbVie is recognized as a leading drugmaker with an extensive portfolio of therapeutics in fields such as immunology, oncology, neuroscience, and eye care. Additionally, the company commercializes the high-profile aesthetics brands Botox and Juvederm as anti-aging skin treatments. This diversification, coupled with a long history of innovation, is a big part of what makes AbbVie a blue chip stock and compelling investment opportunity.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool